Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.135 SEK | +7.92% | +1.51% | -60.51% |
15/04 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
04/04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.51% | 58.65M | |
+3.01% | 108B | |
+11.17% | 104B | |
+1.75% | 22.33B | |
-12.04% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.36% | 17.64B | |
+5.84% | 14.05B | |
+34.91% | 12.51B |
- Stock Market
- Equities
- ONCO Stock
- News Oncopeptides AB
- Oncopeptides Extends Exclusive Rights to Cancer Drug Until 2037